Printer Friendly

PFIZER RESPONDS TO WALL STREET JOURNAL ARTICLE ABOUT THE USE OF PROCARDIA (NIFEDIPINE) IN PATIENTS WHO HAVE SUFFERED HEART ATTACKS

 NEW YORK, Feb. 8 /PRNewswire/ -- Pfizer Inc (NYSE: PFE) issued the following statement in response to an article on its calcium channel blocker Procardia that appeared in today's Wall Street Journal:
 "This issue is not new. The study referred to in the article was completed more than six years ago. The medical community has long been aware of the effects of calcium channel blockers -- including nifedipine -- in post-myocardial infarction (heart attack) patients. The FDA has looked at the topic and it has been reviewed extensively in the medical literature.
 "Pfizer's Procardia and Procardia XL are not approved for use as a treatment to prevent heart attack recurrence, nor does the company recommend that the medicine be used for that purpose. In fact, Pfizer data confirm that there is minimal use of Procardia and Procardia XL in post-heart attack patients. Procardia capsules are approved for the treatment of angina, and Procardia XL is approved for the treatment of angina or hypertension in patients who need them.
 "The study quoted by The Wall Street Journal relates to the drug nifedipine, which is the active ingredient in Procardia capsules. The study does not involve Procardia XL, which has a different mechanism of delivery from that of Procardia capsules, has a different onset of action and a different treatment indication. There is a distinct difference in the way the two medicines affect heart rate and blood circulation.
 "Pfizer is committed first and foremost to the patients who take our medicines. We would like to reassure both physicians and patients that Procardia capsules and Procardia XL have been studied extensively and are well-documented for safety and efficacy in millions of patients. Pfizer will continue to communicate important information to physicians, who remain the best source of medical knowledge for patients."
 -0- 2/8/93
 /CONTACT: A. A. Biesada, 212-573-2055, or Rick Honey, 212-573-2051, both of Pfizer/
 (PFE)


CO: Pfizer Inc ST: New York IN: MTC SU:

GK -- NY077 -- 4151 02/08/93 13:30 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 8, 1993
Words:330
Previous Article:SNAP-ON TO INTEGRATE SUN ELECTRIC SALES FORCE TO CREATE INDUSTRY'S MOST COMPREHENSIVE EQUIPMENT RESOURCE
Next Article:DOCTORS GIVE CONSUMER GUIDELINES ON ARTHRITIS TREATMENTS
Topics:


Related Articles
STERLING WINTHROP RESPONDS TO INACCURATE REPORTING ON HEART DRUG IN THE WALL STREET JOURNAL
COURT DISMISSES PFIZER SUIT AGAINST ELAN
ETHICAL HOLDINGS PLC ANNOUNCES APPROVAL FOR ONCE-DAILY NIFEDIPINE IN THE UNITED KINGDOM
GEOMATRIX(R) NIFEDIPINE
PFIZER AFFIRMS SAFETY AND EFFICACY OF ITS CALCIUM CHANNEL BLOCKERS
UNSUPPORTED CONCLUSIONS ON CALCIUM CHANNEL BLOCKERS MAY AGAIN PRESENT PUBLIC HEALTH THREAT
FLAWED ANALYSIS SHOULD NOT BE BASIS FOR THERAPY DECISIONS
PFIZER PRAISES FDA ADVISORY PANEL RECOMMENDATION TO CLARIFY LABELING OF SHORT-ACTING NIFEDIPINE
LEADING RESEARCHER CONFIRMS PFIZER LONG-ACTING CALCIUM CHANNEL BLOCKERS SAFE FOR HYPERTENSION TREATMENT
Major Studies From Framingham Heart Data Base and Cleveland Clinic Support Safety of Calcium Channel Blockers, Pfizer Says

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters